Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide Review uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Alkylating
  • Central Nervous System Neoplasms
  • Dacarbazine
  • Immunotherapy
  • Lymphoma, B-Cell
  • Salvage Therapy

abstract

  • The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.

publication date

  • September 14, 2004

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 15365145

Additional Document Info

start page

  • 901

end page

  • 3

volume

  • 63

number

  • 5